Compare ALGN & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALGN | ABVX |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | France |
| Employees | N/A | 67 |
| Industry | Industrial Specialties | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 9.7B |
| IPO Year | 2000 | N/A |
| Metric | ALGN | ABVX |
|---|---|---|
| Price | $184.78 | $122.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 13 |
| Target Price | ★ $196.73 | $131.31 |
| AVG Volume (30 Days) | ★ 927.3K | 895.9K |
| Earning Date | 04-29-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.53 | N/A |
| EPS | ★ 5.65 | N/A |
| Revenue | ★ $387,126,000.00 | N/A |
| Revenue This Year | $5.80 | $70.74 |
| Revenue Next Year | $4.59 | $3,694.18 |
| P/E Ratio | $33.02 | ★ N/A |
| Revenue Growth | ★ 23.95 | N/A |
| 52 Week Low | $122.00 | $5.59 |
| 52 Week High | $208.31 | $148.83 |
| Indicator | ALGN | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 58.24 | 54.36 |
| Support Level | $159.99 | $105.48 |
| Resistance Level | $203.25 | $130.20 |
| Average True Range (ATR) | 6.73 | 5.88 |
| MACD | 1.78 | 1.09 |
| Stochastic Oscillator | 83.25 | 79.55 |
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.